Jones Financial Companies Lllp Boosts Stake in argenx SE (NASDAQ:ARGX)

Jones Financial Companies Lllp lifted its holdings in argenx SE (NASDAQ:ARGX) by 1,016.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67 shares of the company’s stock after buying an additional 61 shares during the period. Jones Financial Companies Lllp’s holdings in argenx were worth $41,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ARGX. FMR LLC increased its position in argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in argenx during the third quarter worth about $88,339,000. Allspring Global Investments Holdings LLC increased its position in argenx by 38,152.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after purchasing an additional 143,834 shares during the last quarter. Jennison Associates LLC increased its position in argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after purchasing an additional 64,183 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after purchasing an additional 55,617 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ARGX has been the subject of several recent analyst reports. Robert W. Baird raised their price objective on shares of argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. Wedbush reiterated an “outperform” rating and set a $655.00 price target on shares of argenx in a research report on Tuesday, December 3rd. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday. HC Wainwright lifted their price target on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Finally, Citigroup reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Trading Down 0.5 %

Shares of NASDAQ:ARGX opened at $611.18 on Wednesday. The company has a market capitalization of $37.14 billion, a PE ratio of -694.52 and a beta of 0.59. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The firm has a 50 day simple moving average of $636.83 and a 200-day simple moving average of $598.22.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.